TRX-211 / Therapex, Huons - LARVOL DELTA

Discovery of TRX-211-399, a potent, CNS-penetrant, highly selective inhibitor of EGFR exon 20 insertion mutations (AACR 2024) - "Recently, as mobocertinib (EXKIVITY®) failed to improve progression-free survival in Phase 3 clinical trial, there remains a high unmet medical need to develop new drugs with wider therapeutic window to treat NSCLC harboring EGFR ex20ins mutations. Furthermore, in a PC-9-luc cell intracranial xenograft model, TRX-211-399 induced substantial anti-tumor effects and prolonged survival without body weight loss. TRX-211-399 is currently undergoing further preclinical evaluation as a potential candidate for clinical development for patients with EGFR exon20ins mutations."

EGFR exon 20 • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Huons acquires TRX-211 lung cancer candidate from Teraphex (Chosun Biz) - "Under the agreement, the company will lead the clinical development of TRX-211, which is in the preclinical stage. After approval, it will hold the domestic marketing rights. It may also exercise an option for global rights in the future."

Commercial • EGFR exon 20 • Non Small Cell Lung Cancer